ArticleHead & neck2021
A cause-specific Cox model for second primary tumors in patients with head and neck cancer: A RONCDOC study.
Article in Head & neck, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Factors associated with the development of second primary tumours in head and neck cancer patients.European journal of cancer care · 2022Pooled it
- Distinct Second Primary Tumor Phenotypes in Oral Squamous Cell Carcinoma According to Exposure Status and Immune Background.Journal of clinical medicine · 2026Article
- Machine learning-based prognostic model for local control prediction in lung cancer patients undergoing stereotactic body radiation therapy: a preliminary study.European journal of medical research · 2026Article
- Oral cancer in women: clinical profile, risk factors, treatment outcomes and survival predictors in 32 years of experience.Clinical oral investigations · 2025Article
- Tumor behavior disparities in all-cause and cause-specific mortality among patients with central nervous system tumors.Scientific reports · 2025Article
- Mutagen sensitivity and risk of second cancer in younger adults with head and neck squamous cell cancer: 15-year results.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Article
- Endoscopic Screening for Second Primary Tumors of the Esophagus Among Head and Neck Cancer Patients.Frontiers in oncology · 2022Review
- Developing a Stacked Ensemble-Based Classification Scheme to Predict Second Primary Cancers in Head and Neck Cancer Survivors.International journal of environmental research and public health · 2021Article
- A cause-specific Cox model for second primary tumors in patients with head and neck cancer: A RONCDOC study.Head & neck · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to identify risk factors for the development of second primary tumors (SPTs) in the head and neck region, lungs, and esophagus in patients with head and neck cancer.
methodsWe collected data from 1581 patients. A cause-specific Cox model for the development of an SPT was fitted, accounting for the competing risks residual/recurrent tumor and mortality.
resultsOf all patients, 246 (15.6%) developed SPTs. Analysis showed that tobacco and alcohol use, comorbidity, and the oral cavity subsite were risk factors for SPTs. The C-index, the discriminative accuracy, of the model for SPT was 0.65 (95% confidence interval, 0.61-0.68).
conclusionsOur results show that there is potential to identify patients who have an increased risk to develop an SPT. This might increase their survival chances and quality of life. More research is needed to provide head and neck clinicians with definitive recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.